NCT01789281 2021-06-11
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Novartis
Phase 4 Completed
Novartis
Novartis
Novartis
Dana-Farber Cancer Institute
Novartis
Dana-Farber Cancer Institute